NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $46.5455.

A number of research analysts have weighed in on NAMS shares. Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Leerink Partners reaffirmed an “outperform” rating and issued a $55.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. Wall Street Zen cut NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Finally, Guggenheim boosted their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, February 19th.

NewAmsterdam Pharma Price Performance

NAMS opened at $35.46 on Tuesday. NewAmsterdam Pharma has a 1 year low of $14.06 and a 1 year high of $42.00. The stock has a market cap of $4.08 billion, a P/E ratio of -20.50 and a beta of 0.06. The firm has a fifty day moving average price of $34.06 and a 200 day moving average price of $33.01.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%.The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. Equities analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Insider Activity

In related news, insider Johannes Jacob Piete Kastelein sold 45,481 shares of the stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $35.31, for a total value of $1,605,934.11. Following the completion of the transaction, the insider directly owned 53,500 shares in the company, valued at approximately $1,889,085. This represents a 45.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Louise Frederika Kooij sold 32,612 shares of NewAmsterdam Pharma stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $31.80, for a total value of $1,037,061.60. Following the completion of the sale, the chief accounting officer owned 24,353 shares in the company, valued at $774,425.40. This represents a 57.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 650,421 shares of company stock valued at $22,417,631. 20.84% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its holdings in NewAmsterdam Pharma by 4,425.0% during the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after acquiring an additional 708 shares during the period. Mather Group LLC. acquired a new stake in shares of NewAmsterdam Pharma during the third quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of NewAmsterdam Pharma in the third quarter valued at approximately $30,000. Wells Fargo & Company MN grew its holdings in shares of NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares in the last quarter. Finally, Navalign LLC purchased a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $46,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.